Bayer Stock’s Summer of Reckoning: Glyphosate Verdict, Trade Probe and Pipeline Wins Collide

Bayer shares near €38 as US Supreme Court glyphosate ruling, Section 301 drug pricing probe, and new FDA approval create a pivotal week for the German group.

Bayer shares closed last week at €37.81, having nudged back above the 50-day moving average — a technical foothold that belies the thicket of legal, political and commercial events bearing down on the German drug and crop-science group over the next few weeks. The stock has recouped more than 50 percent from its 52-week trough of €25.09, yet remains nearly flat on a 12-month view. The coming days will determine whether that recovery has legs or stalls under the weight of three simultaneous flashpoints.

Supreme Court Ruling Could Reshape Glyphosate Exposure

The most binary catalyst arrives this week when the US Supreme Court is expected to issue its verdict in the “Durnell” glyphosate case. At stake is a pre-emption question: can a company be held liable under state law for a product the federal Environmental Protection Agency has deemed safe? A favourable ruling for Bayer would render the bulk of roughly 65,000 outstanding claims moot. An adverse outcome would keep the litigation machine running. The glyphosate saga has already cost the group more than $10 billion, and in February Bayer proposed a $7 billion settlement to draw a line under future cases.

The Court has until the end of June to deliver its opinion. Whatever the outcome, it will set the tone for two other scheduled events: the final hearing on the multi-billion-dollar settlement in St. Louis on 9 July 2026, and a US hearing in September on possible retaliatory tariffs tied to German healthcare reforms.

Washington Opens a Second Front on Drug Pricing

Separately, US Trade Representative Jamieson Greer has launched a Section 301 investigation into Germany’s drug-pricing policies, arguing they disadvantage American patients and manufacturers. The probe was triggered by Berlin’s planned savings package for the statutory health insurance system, which aims to close a hole of roughly €20 billion. A vote in the Bundestag has been pushed to July 2026. Washington plans to publish public comments in August and hold a hearing in September.

Bayer operates key R&D and production sites in Germany. If the investigation leads to tariffs on German pharmaceuticals, the company would need to recalculate margins in its North American business — a region that accounts for a significant slice of its drug revenue. The trade threat adds a layer of uncertainty that the Supreme Court ruling, depending on its direction, could either amplify or partially offset.

Pipeline Progress and Patent Battles

Amid the legal noise, Bayer has quietly made strides in its pharmaceutical pipeline. On 15 June the FDA approved AMBELVIST® (Gadoquatrane), a new MRI contrast agent with the lowest approved dose in the United States. Japan gave the green light in March 2026, and applications are pending in the European Union and China.

Two days later, Bayer closed the acquisition of Perfuse Therapeutics, gaining full rights to PER-001, an intravitreal implant in Phase II trials for glaucoma and diabetic retinopathy. The upfront cost was $300 million, with milestone payments that could push the total consideration to $2.45 billion. The deal bolsters the ophthalmology division — a strategic focus area.

On the legal front, Bayer filed an amended lawsuit against Johnson & Johnson on 15 June, accusing J&J of promoting its prostate cancer drug Erleada as superior to Bayer’s Nubeqa based on a flawed real-world analysis. Bayer is seeking a permanent injunction and damages.

Institutional Investors Trim Stakes Ahead of Verdict

The regulatory filings tell a cautionary tale. The government of Singapore cut its voting rights stake to 2.90 percent from 4.17 percent, while Goldman Sachs reduced its position to 4.84 percent on 15 June, down from 5.40 percent just three days earlier. These moves may reflect portfolio rebalancing ahead of the Supreme Court decision, but they underscore the nervousness surrounding Bayer’s biggest overhang.

Brighter Regulatory Outlook for Crop Science

The legal clouds are not the whole story. The European Parliament has voted to exempt plants modified with techniques such as CRISPR/Cas from strict EU labelling requirements, with new rules expected to take effect in mid-2028. Bayer and Corteva together hold roughly 80 percent of the relevant patents, positioning the German group as one of the biggest beneficiaries of the liberalisation. The crop science division, long overshadowed by glyphosate litigation, could see a meaningful tailwind.

Technicals Point to a Defining Few Weeks

The share price ended the week at €37.81 — almost exactly at the 50-day moving average of €37.80. On a 12-month basis the stock has advanced 43 percent, but it remains 24 percent below the 52-week high of €49.93 reached in February. A positive Supreme Court ruling could trigger a swift re-rating as the market prices out the litigation risk. A negative one, combined with the escalating trade probe, would leave the stock fighting headwinds on multiple fronts.

Three decisions in three months — the Supreme Court, the settlement hearing and the trade tariffs hearing — will collectively determine whether Bayer’s technical breakout becomes the start of a sustained recovery or another false dawn.